BLU BELLUS Health
- 14.740
- 0.0000.00%
BELLUS Health News
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as pate
News On BELLUS Health Inc. (BLU) Now Under GSK.LN
News On BELLUS Health Inc. (BLU) Now Under GSK.LN
Stock-exchange Announcement - For Media and Investors Only - GSK Completes Acquisition of BELLUS Health
Express News | Stock-exchange Announcement - For Media And Investors Only - GSK Completes Acquisition Of BELLUS Health >GSK.LN BLU.T
GSK PLC Has Bought Bellus For $2.0B
GSK PLC Has Bought Bellus For $2.0B
GSK PLC Completes Acquisition of BELLUS Health
GSK PLC Completes Acquisition of BELLUS Health
BTIG Reaffirms Their Hold Rating on BELLUS Health (BLU)
Catalyst Watch: AI Talk From Salesforce and AMD, Shell Event and Oracle Earnings
Express News | BELLUS Health: Special Meeting to Be Held on June 16 >BLU
BELLUS Health Inc. Calls Special Shareholders' Meeting in Connection With GSK Acquisition
BELLUS Health Inc. Calls Special Shareholders' Meeting in Connection With GSK Acquisition
RBC Capital Sticks to Their Hold Rating for BELLUS Health (BLU)
RBC Capital on Bellus Health
Following the GSK acquisition announcement of Bellus Health on 4/18 for US$14.75 per share in cash for a total value of ~$2 billion, management reiterated its expectation for the transaction to close
RBC Capital Reiterates Sector Perform on BELLUS Health, Maintains $14.75 Price Target
RBC Capital analyst Gregory Renza reiterates BELLUS Health (NASDAQ:BLU) with a Sector Perform and maintains $14.75 price target.
BELLUS Health: Q1 Earnings Insights
BELLUS Health (NASDAQ:BLU) reported its Q1 earnings results on Friday, May 12, 2023 at 04:00 PM.Here's what investors need to know about the announcement.EarningsBELLUS Health missed estimated earning
BELLUS Health GAAP EPS of -$0.20, Revenue of $3K
BELLUS Health Q1 EPS $(0.20) Misses $(0.18) Estimate, Sales $3.00K Down From $4.00K YoY
BELLUS Health (NASDAQ:BLU) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 53.85 percent decrease over losses of $(0.1
BELLUS Health Brief: Bid Represented an Approximate Total Equity Value of US$2.0 Billion and a Premium of Approximately 103%; Transaction Expected to Close in Q3 2023
04:04 PM EDT, 05/12/2023 (MT Newswires) -- BELLUS Health Brief: Bid Represented an approximate total equity value of US$2.0 billion and a premium of approximately 103%; transaction expected to close i
BELLUS Health Brief: Comes After Co Announced Agreement to Be Acquired by GSK for US$14.75 per Share of Common Stock in Cash
04:03 PM EDT, 05/12/2023 (MT Newswires) -- BELLUS Health Brief: Comes After Co Announced agreement to be Acquired by GSK for US$14.75 per share of common stock in cash
BELLUS Health Brief: For the Quarter Ended March 31, 2023, Net Loss Amounted to US$25.1 Million (US$0.20 per Share
04:02 PM EDT, 05/12/2023 (MT Newswires) -- BELLUS Health Brief: For the quarter ended March 31, 2023, net loss amounted to US$25.1 million (US$0.20 per share
BELLUS Health 1Q Loss/Shr $0.20 >BLU
BELLUS Health 1Q Loss/Shr $0.20 >BLU
Analysis
Price Target
No Data
